PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients.

Q3 Medicine

Journal of Circulating Biomarkers Pub Date : 2023-02-17 eCollection Date: 2023-01-01 DOI:10.33393/jcb.2023.2453

Tanita Suttichaimongkol, Manoon Mitpracha, Kawin Tangvoraphonkchai, Phuangphaka Sadee, Kittisak Sawanyawisuth, Wattana Sukeepaisarnjaroen

{"title":"PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients.","authors":"Tanita Suttichaimongkol, Manoon Mitpracha, Kawin Tangvoraphonkchai, Phuangphaka Sadee, Kittisak Sawanyawisuth, Wattana Sukeepaisarnjaroen","doi":"10.33393/jcb.2023.2453","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is a lethal cancer. Two biomarkers were used for HCC diagnosis including alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II or antagonist (PIVKA-II). However, data on biomarkers and HCC diagnosis are not consistent. This study aimed to evaluate if PIVKA-II, AFP, or a combination of both biomarkers had the best diagnostic properties for HCC.Methods: This was a prospective study and enrolled patients 18 years or over with a high risk for HCC. AFP and PIVKA-II levels were calculated for HCC diagnosis. Diagnostic properties of both biomarkers were reported with sensitivity, specificity, and a receiver operating characteristic (ROC) curve.Results: There were 260 patients with high risk for HCC in this cohort. Of those, 219 patients were diagnosed with HCC: confirmed by biopsy in 7 patients (2.69%) and by imaging in the others. Median values of AFP and PIVKA-II were 56 ng/mL and 348 mAU/mL, respectively. PIVKA-II level of 40 mAU/mL had sensitivity of 80.80%, while AFP of 10 ng/mL had sensitivity of 75.80%. A combination of PIVKA-II at 100 mAU/mL or over and AFP of 11 ng/mL gave sensitivity of 60.30%. The ROC curve of PIVKA-II plus AFP was significantly higher than the AFP alone (0.855 vs. 0.796; p = 0.027), but not significantly different from the PIVKA-II alone (0.855 vs. 0.832; p = 0.130).Conclusion: PIVKA-II may have more diagnostic yield for HCC compared with AFP. It can be used alone without a combination with AFP.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/29/jcb-12-12.PMC9952284.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Circulating Biomarkers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/jcb.2023.2453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is a lethal cancer. Two biomarkers were used for HCC diagnosis including alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II or antagonist (PIVKA-II). However, data on biomarkers and HCC diagnosis are not consistent. This study aimed to evaluate if PIVKA-II, AFP, or a combination of both biomarkers had the best diagnostic properties for HCC.

Methods: This was a prospective study and enrolled patients 18 years or over with a high risk for HCC. AFP and PIVKA-II levels were calculated for HCC diagnosis. Diagnostic properties of both biomarkers were reported with sensitivity, specificity, and a receiver operating characteristic (ROC) curve.

Results: There were 260 patients with high risk for HCC in this cohort. Of those, 219 patients were diagnosed with HCC: confirmed by biopsy in 7 patients (2.69%) and by imaging in the others. Median values of AFP and PIVKA-II were 56 ng/mL and 348 mAU/mL, respectively. PIVKA-II level of 40 mAU/mL had sensitivity of 80.80%, while AFP of 10 ng/mL had sensitivity of 75.80%. A combination of PIVKA-II at 100 mAU/mL or over and AFP of 11 ng/mL gave sensitivity of 60.30%. The ROC curve of PIVKA-II plus AFP was significantly higher than the AFP alone (0.855 vs. 0.796; p = 0.027), but not significantly different from the PIVKA-II alone (0.855 vs. 0.832; p = 0.130).

Conclusion: PIVKA-II may have more diagnostic yield for HCC compared with AFP. It can be used alone without a combination with AFP.

Abstract Image

查看原文本刊更多论文

PIVKA-II 或 AFP 对高危患者的肝细胞癌诊断具有更好的诊断性能。

背景：肝细胞癌（HCC）是一种致命的癌症。有两种生物标志物被用于诊断 HCC，包括甲胎蛋白（AFP）和维生素 K 缺乏-II 或拮抗剂诱导的蛋白质（PIVKA-II）。然而，有关生物标志物和 HCC 诊断的数据并不一致。本研究旨在评估 PIVKA-II、AFP 或两种生物标志物的组合是否具有最佳的 HCC 诊断特性：这是一项前瞻性研究，研究对象为 18 岁或以上的 HCC 高危患者。在诊断 HCC 时计算了 AFP 和 PIVKA-II 的水平。报告了这两种生物标记物的诊断特性，包括敏感性、特异性和接收者操作特征曲线（ROC）：结果：该队列中有 260 名 HCC 高危患者。其中，219 名患者被确诊为 HCC：7 名患者（2.69%）通过活组织检查确诊，其他患者通过影像学检查确诊。AFP和PIVKA-II的中位值分别为56纳克/毫升和348毫安单位/毫升。PIVKA-II 水平为 40 毫安单位/毫升时，灵敏度为 80.80%，而 AFP 水平为 10 纳克/毫升时，灵敏度为 75.80%。PIVKA-II 为 100 毫安单位/毫升或以上和 AFP 为 11 纳克/毫升的组合灵敏度为 60.30%。PIVKA-II 加 AFP 的 ROC 曲线明显高于单用 AFP 的 ROC 曲线（0.855 vs. 0.796; p = 0.027），但与单用 PIVKA-II 的 ROC 曲线（0.855 vs. 0.832; p = 0.130）无明显差异：结论：与 AFP 相比，PIVKA-II 对 HCC 的诊断率更高。结论：与 AFP 相比，PIVKA-II 对 HCC 的诊断率可能更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Circulating Biomarkers Medicine-Biochemistry (medical)

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： Journal of Circulating Biomarkers is an international, peer-reviewed, open access scientific journal focusing on all aspects of the rapidly growing field of circulating blood-based biomarkers and diagnostics using circulating protein and lipid markers, circulating tumor cells (CTC), circulating cell-free DNA (cfDNA) and extracellular vesicles, including exosomes, microvesicles, microparticles, ectosomes and apoptotic bodies. The journal publishes high-impact articles that deal with all fields related to circulating biomarkers and diagnostics, ranging from basic science to translational and clinical applications. Papers from a wide variety of disciplines are welcome; interdisciplinary studies are especially suitable for this journal. Included within the scope are a broad array of specialties including (but not limited to) cancer, immunology, neurology, metabolic diseases, cardiovascular medicine, regenerative medicine, nosology, physiology, pathology, technological applications in diagnostics, therapeutics, vaccine, drug delivery, regenerative medicine, drug development and clinical trials. The journal also hosts reviews, perspectives and news on specific topics.